NCT02465307

Brief Summary

Delirium, as a common complication of hospitalization, poses significant health problems in hospitalized patients. Though about a third of delirium cases can benefit from intervention, detecting and predicting delirium is still very limited in practice. A common characterization of delirium is change in activity level, causing patients to become hyperactive or hypoactive which is manifested in facial expressions and total body movements. This pilot study is designed to test the feasibility of a delirium detection system using movement data obtained from 3-axis wearable accelerometers and commercially available camera with facial recognition video system in conjunction with electronics medical record (EMR) data to analyze the relation of whole-body movement and facial expressions with delirium.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
130

participants targeted

Target at P50-P75 for all trials

Timeline
25mo left

Started Feb 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress83%
Feb 2016May 2028

First Submitted

Initial submission to the registry

May 29, 2015

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 8, 2015

Completed
8 months until next milestone

Study Start

First participant enrolled

February 1, 2016

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 11, 2020

Completed
8.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2028

Expected
Last Updated

June 29, 2025

Status Verified

June 1, 2025

Enrollment Period

4.1 years

First QC Date

May 29, 2015

Last Update Submit

June 27, 2025

Conditions

Keywords

ConsciousnessAlertnessCognitionActivity levelDeliriumHyperactive deliriumHypoactive deliriumFacial expressionPostureIntensive care unit

Outcome Measures

Primary Outcomes (4)

  • CAM/CAM-ICU

    Confusion Assessment Method for detection of delirium

    Changes from Baseline up to 7 Days

  • Memorial Delirium Assessment Scale (MDAS) will be used for changes from baseline up to 7 days between the groups.

    MDAS denotes motor profile and defines motor subtyping. It has 10 items which assesses several areas of cognitive functioning (memory, attention, orientation and disturbances in thinking) and psychomotor activity. The items are rated on a four point scale (0-3) based on the current interaction with the patient or by assessment of behavior. A score of 13 shows the diagnosis of delirium.

    Changes from Baseline up to 7 Days

  • Delirium Motor Subtyping Scale (DMSS-4) will be used for changes from baseline up to 7 days between the groups.

    Scoring from DMSS-4 which has 5 hyperactive and 8 hypoactive symptoms requires at least two symptoms to be present from either the hyperactive or hypoactive list to meet subtype criteria. The higher the score the higher the delirium.

    Changes from Baseline up to 7 Days

  • Freedman Sleep Scale

    To determine sleep quality of patient for given day.

    Changes from Baseline up to 7 Days

Secondary Outcomes (2)

  • Number of subjects who died

    Baseline up to 7 Days

  • Number of subjects on mechanical ventilation

    greater than 48 hours

Other Outcomes (2)

  • Facial amimia versus non-amimia expressions between the groups

    Changes from Baseline up to 7 Days

  • Dynamic activity versus static position

    Changes from Baseline up to 7 Days

Study Arms (3)

Delirium group

ICU patients with a positive Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).

Behavioral: Confusion Assessment MethodDevice: AccelerometerDevice: Commercially available cameraDevice: Internet Pod (iPod)

Control group

ICU patients with a negative Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).

Behavioral: Confusion Assessment MethodDevice: AccelerometerDevice: Commercially available cameraDevice: Internet Pod (iPod)

Healthy control group

Healthy subjects that sleep in their home environment; observational using accelerometers, cortisol swabs, and Internet Pod (iPod)

Device: AccelerometerDevice: Internet Pod (iPod)Diagnostic Test: Cortisol Swab

Interventions

Confusion Assessment Method (CAM) score

Control groupDelirium group

3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor

Control groupDelirium groupHealthy control group

As part of facial recognition video system

Also known as: imaging
Control groupDelirium group

Monitors noise levels in the room

Also known as: Sound detection
Control groupDelirium groupHealthy control group
Cortisol SwabDIAGNOSTIC_TEST

Cortisol level collected through self administered salivary swab

Healthy control group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

ICU Patients: Patients who been hospitalized in an intensive care unit and have risk factors to develop delirium or delirium has been suspected by their medical provider. Healthy Controls: People who are healthy and sleep in their home environment.

You may qualify if:

  • Intensive care unit patient
  • years of age or older

You may not qualify if:

  • Anticipated intensive care unit stay less than one day
  • Less than 18 years of age
  • Inability to wear a motion sensor watch (ActiGraph)
  • years of age or older.
  • sleeps in home environment
  • does not sleep in home environment
  • Less than 18 years of age
  • Inability to wear a motion sensor watch (ActiGraph)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UF Health

Gainesville, Florida, 32610, United States

Location

MeSH Terms

Conditions

DeliriumConfusionFacial Expression

Interventions

Diagnostic Imaging

Condition Hierarchy (Ancestors)

Neurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsNeurocognitive DisordersMental DisordersNonverbal CommunicationCommunicationBehavior

Intervention Hierarchy (Ancestors)

Diagnostic Techniques and ProceduresDiagnosis

Study Officials

  • Azra Bihorac, MD

    University of Florida

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 29, 2015

First Posted

June 8, 2015

Study Start

February 1, 2016

Primary Completion

March 11, 2020

Study Completion (Estimated)

May 30, 2028

Last Updated

June 29, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations